Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.

MLA

Xu, Pengfei, et al. “Proteostasis Perturbation of N-Myc Leveraging HSP70 Mediated Protein Turnover Improves Treatment of Neuroendocrine Prostate Cancer.” Nature Communications, vol. 15, no. 1, Aug. 2024, p. 6626. EBSCOhost, https://doi.org/10.1038/s41467-024-50459-x.

APA

Xu, P., Yang, J. C., Chen, B., Ning, S., Zhang, X., Wang, L., Nip, C., Shen, Y., Johnson, O. T., Grigorean, G., Phinney, B., Liu, L., Wei, Q., Corey, E., Tepper, C. G., Chen, H.-W., Evans, C. P., Dall’Era, M. A., Gao, A. C., … Liu, C. (2024). Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nature Communications, 15(1), 6626. https://doi.org/10.1038/s41467-024-50459-x

Chicago

Xu, Pengfei, Joy C Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang, Christopher Nip, et al. 2024. “Proteostasis Perturbation of N-Myc Leveraging HSP70 Mediated Protein Turnover Improves Treatment of Neuroendocrine Prostate Cancer.” Nature Communications 15 (1): 6626. doi:10.1038/s41467-024-50459-x.